ICUI stock icon

ICU Medical
ICUI

$128.03
2.86%

Market Cap: 3.12B

 

About: ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Employees: 14,000

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

44% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 70

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

12% more capital invested

Capital invested by funds: $2.15B [Q4 2023] → $2.4B (+$250M) [Q1 2024]

3.32% more ownership

Funds ownership: 89.11% [Q4 2023] → 92.42% (+3.32%) [Q1 2024]

3% more funds holding

Funds holding: 238 [Q4 2023] → 244 (+6) [Q1 2024]

41% less call options, than puts

Call options by funds: $1.59M | Put options by funds: $2.68M

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$134
5%
upside
Avg. target
$135
5%
upside
High target
$136
6%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Raymond James
Jayson Bedford
5%upside
$135
Outperform
Upgraded
17 Jun 2024
Keybanc
Brett Fishbin
6%upside
$136
Overweight
Maintained
28 Feb 2024
Keybanc
Brett Fishbin
5%upside
$134
Overweight
Initiated
6 Feb 2024

Financial journalist opinion